Therapy News and Research

RSS

Health experts address treatment gap in epilepsy management at AES Annual Meeting

Substantial progress has been made over the last 15 years in the healthcare community's ability to diagnose and treat epilepsy and its complications. Yet this progress in epilepsy management has not reached most of the 50 million people around the world, including many of the nearly three million people in the United States who have the disorder.

5 Dec 2009

Jenex reports closing of modified private-placement equity financing

The Jenex Corporation, a medical device company focused on the development and application of products based on its patented thermal therapy technology, today announced that on December 1, 2009 it closed a brokered private-placement equity financing. The offering is subject to receiving final acceptance from The TSX Venture Exchange.

5 Dec 2009

Hospira launches VisIV containers for intravenous medications and solutions

Hospira, Inc., a leading global specialty pharmaceutical and medication delivery company, today announced the launch of its next-generation 50 mL and 100 mL VisIV(TM) containers for intravenous (I.V.) medications and solutions, and now offers a complete size range (50 mL to 1 L) of the award-winning, environmentally responsible VisIV product.

5 Dec 2009

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

The U.S. Food and Drug Administration (FDA) today approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old.

4 Dec 2009

Rituximab drug may reduce long-term complications of type 1 diabetes

New findings by UT Southwestern researchers suggest that a drug already used to treat autoimmune disorders might also help slow the destruction of insulin-producing cells in patients recently diagnosed with insulin-dependent (type 1) diabetes.

4 Dec 2009

First patient treated in Carticept Medical's Cartiva SCI study

Carticept Medical, Inc., a developer of innovative products for the treatment of cartilage injuries and osteoarthritis, today announced that the first patient has been treated in an international, multi-center study of the Company's Cartiva Synthetic Cartilage Implant (SCI). The study aims to determine the effectiveness of Cartiva SCI in comparison to arthrodesis (joint fusion), the current standard of care, for reducing the debilitating pain associated with osteoarthritis of the first metatarsophalangeal (MTP) joint.

4 Dec 2009

Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting

Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chronic myeloid leukemia (CML) have been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009.

4 Dec 2009

Axsun Technologies reports successful testing of novel OCT imaging integrated light source architecture

Axsun Technologies, Inc., a wholly-owned subsidiary of Volcano Corporation, today announced the initial development and successful testing of a novel integrated light source architecture for OCT imaging. Axsun believes this proprietary optical engine design raises the bar on imaging speed and overcomes fundamental limitations of laser-based designs for swept source OCT light sources.

4 Dec 2009

Pfizer to present study findings from its expanded breast cancer portfolio

Pfizer Oncology announced today that it will be presenting study findings evaluating several compounds including those from its newly expanded breast cancer portfolio following the recent acquisition of Wyeth, focusing on the needs of multiple breast cancer patient populations at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) being held December 9 – 13.

4 Dec 2009

Cyberonics' FDA-approved VNS Therapy to be featured at the AES meeting

Cyberonics, Inc. announced today that Vagus Nerve Stimulation (VNS) Therapy, the only FDA-approved implantable medical device for the treatment of refractory epilepsy, will be featured in 14 presentations at the American Epilepsy Society's (AES) Annual Meeting, taking place December 4-8 at the Hynes Convention Center in Boston, Massachusetts.

4 Dec 2009

FDA approves St. Jude Medical's Penta surgical lead for neurostimulation therapy

St. Jude Medical, Inc. today announced the U.S. Food and Drug Administration (FDA) approval and U.S. market introduction of its new Penta™ surgical lead for neurostimulation therapy. Unveiled at the annual North American Neuromodulation Society meeting, the Penta lead is the first of its kind, featuring the smallest electrodes in the market arranged in five columns.

4 Dec 2009

IMF to stage presentation on multiple myeloma at ASH annual meeting

The International Myeloma Foundation (IMF)—supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians—today said presentations at the annual meeting of the American Society of Hematology (ASH) will cover all stages of multiple myeloma, a major milestone in treating this and related cancers.

4 Dec 2009

DCVax therapeutic cancer vaccine manufacturing process receives patent approval

Northwest Biotherapeutics, Inc. ("NWBT" or the "Company") announced today that the US Patent and Trademark Office has allowed its patent application on a system for automation of the initial stages of the manufacture of the Company's DCVax® therapeutic cancer vaccines.

4 Dec 2009

FDA approves once-daily SEROQUEL XR Extended Release Tablets

AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tablets as adjunctive (add-on) treatment to antidepressants in adults with Major Depressive Disorder (MDD).

4 Dec 2009

New discoveries to treat life-threatening blood disorder presented at ASH annual meeting

A genetic variation that may indicate a patient's risk of developing a potentially life-threatening blood disorder if exposed to certain pharmaceutical therapies or chemicals is one of several medical discoveries scientists at cancer diagnostics leader Quest Diagnostics will present during the 51st American Society of Hematology (ASH) Annual Meeting and Exposition, December 5-8, 2009, in New Orleans, LA.

4 Dec 2009

Amgen/GSK's Prolia will be preferred as second- or third-line therapy for osteoporosis

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed clinicians say they will use Amgen/GlaxoSmithKline's Prolia as either a second- or third-line therapy for osteoporosis if the drug receives regulatory approval for the indication.

4 Dec 2009

PRP shows strong potential for accelerated healing of dental implant procedures

An exciting treatment gaining acceptance in orthopedics and sports medicine, called platelet-rich plasma therapy (PRP), is showing strong potential for accelerated healing of dental implant procedures, according to a prominent dental researcher and editor of the Journal of Oral Implantology.

4 Dec 2009

Type 2 diabetics with CAD experience greater antiplatelet activity with prasugrel compared to clopidogrel

Results from a new study showed patients with type 2 diabetes who also had coronary artery disease (CAD) experienced greater antiplatelet activity with the investigational antiplatelet drug prasugrel compared to Plavix(R) (clopidogrel). Patients who received a 60 mg loading dose and 10 mg maintenance dose of prasugrel achieved significantly greater platelet inhibition compared with a 600 mg loading dose and 150 mg maintenance dose of Plavix.

4 Dec 2009

Research study investigates how music therapy can help mentally ill children and young people

Queen's University Belfast is to play a major role in the biggest trial ever conducted to investigate how music therapy can help children and young people with severe mental health problems.

4 Dec 2009

New SPC3649 drug found effective in treating HCV infections

In a dramatic finding, a new drug for hepatitis C virus (HCV) infections that targets liver cells produced a substantial drop in blood levels of the virus in animals and continued to work up to several months after treatment, say scientists at the Southwest Foundation for Biomedical Research (SFBR) in San Antonio.

4 Dec 2009

Therapy News and Research

Health experts address treatment gap in epilepsy management at AES Annual Meeting

Jenex reports closing of modified private-placement equity financing

Hospira launches VisIV containers for intravenous medications and solutions

FDA approves Zyprexa in tablet form for schizophrenia and manic treatment

Rituximab drug may reduce long-term complications of type 1 diabetes

First patient treated in Carticept Medical's Cartiva SCI study

Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting

Axsun Technologies reports successful testing of novel OCT imaging integrated light source architecture

Pfizer to present study findings from its expanded breast cancer portfolio

Cyberonics' FDA-approved VNS Therapy to be featured at the AES meeting

FDA approves St. Jude Medical's Penta surgical lead for neurostimulation therapy

IMF to stage presentation on multiple myeloma at ASH annual meeting

DCVax therapeutic cancer vaccine manufacturing process receives patent approval

FDA approves once-daily SEROQUEL XR Extended Release Tablets

New discoveries to treat life-threatening blood disorder presented at ASH annual meeting

Amgen/GSK's Prolia will be preferred as second- or third-line therapy for osteoporosis

PRP shows strong potential for accelerated healing of dental implant procedures

Type 2 diabetics with CAD experience greater antiplatelet activity with prasugrel compared to clopidogrel

Research study investigates how music therapy can help mentally ill children and young people

New SPC3649 drug found effective in treating HCV infections

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News